TY - JOUR
T1 - Mapping and predicting mortality from systemic sclerosis
AU - Elhai, Muriel
AU - Meune, Christophe
AU - Boubaya, Marouane
AU - Avouac, Jérôme
AU - Hachulla, Eric
AU - Balbir-Gurman, Alexandra
AU - Riemekasten, Gabriela
AU - Airò, Paolo
AU - Joven, Beatriz
AU - Vettori, Serena
AU - Cozzi, Franco
AU - Ullman, Susanne
AU - Czirják, László
AU - Tikly, Mohammed
AU - Müller-Ladner, Ulf
AU - Caramaschi, Paola
AU - Distler, Oliver
AU - Iannone, Florenzo
AU - Ananieva, Lidia P.
AU - Hesselstrand, Roger
AU - Becvar, Radim
AU - Gabrielli, Armando
AU - Damjanov, Nemanja
AU - Salvador, Maria J.
AU - Riccieri, Valeria
AU - Mihai, Carina
AU - Szücs, Gabriella
AU - Walker, Ulrich A.
AU - Hunzelmann, Nicolas
AU - Martinovic, Duska
AU - Smith, Vanessa
AU - Müller, Carolina De Souza
AU - Montecucco, Carlo Maurizio
AU - Opris, Daniela
AU - Ingegnoli, Francesca
AU - Vlachoyiannopoulos, Panayiotis G.
AU - Stamenkovic, Bojana
AU - Rosato, Edoardo
AU - Heitmann, Stefan
AU - Distler, Jörg H.W.
AU - Zenone, Thierry
AU - Seidel, Matthias
AU - Vacca, Alessandra
AU - Langhe, Ellen De
AU - Novak, Srdan
AU - Cutolo, Maurizio
AU - Mouthon, Luc
AU - Henes, Jörg
AU - Chizzolini, Carlo
AU - Mühlen, Carlos Alberto Von
AU - Solanki, Kamal
AU - Rednic, Simona
AU - Stamp, Lisa
AU - Anic, Branimir
AU - Santamaria, Vera Ortiz
AU - Santis, Maria De
AU - Yavuz, Sule
AU - Sifuentes-Giraldo, Walter Alberto
AU - Chatelus, Emmanuel
AU - Stork, Jiri
AU - Laar, Jacob Van
AU - Loyo, Esthela
AU - De La Peña Lefebvre, Paloma Garcia
AU - Eyerich, Kilian
AU - Cosentino, Vanesa
AU - Alegre-Sancho, Juan Jose
AU - Kowal-Bielecka, Otylia
AU - Rey, Grégoire
AU - Matucci-Cerinic, Marco
AU - Allanore, Yannick
N1 - Funding Information:
Funding this study was funded by the “Institut national de la santé et de la recherche médicale (InSErM)” (French national Health and Medical research Institute).
Funding Information:
Competing interests od reports personal fees from 4d Science, grants and personal fees from Actelion, personal fees from Active Biotech, grants and personal fees from Bayer, personal fees from Biogen Idec, personal fees from BMS, grants and personal fees from Boehringer Ingelheim, personal fees from ChemomAb, personal fees from Epipharm, personal fees from Esperare Foundation, personal fees from Genentech/roche, personal fees from GSK, personal fees from Inventiva, personal fees from Lilly, personal fees from Medac, personal fees from Mepha, personal fees from MedImmune, personal fees from pharmacyclics, grants and personal fees from pfizer, grants and personal fees from Sanofi, personal fees from Serodapharm, personal fees from Sinoxa, personal fees from AbbVie, personal fees from iQone Healthcare, outside the submitted work. In addition, od has a patent mir-29 for the treatment of systemic sclerosis licensed. FI reports personal fees from AbbVie, personal fees from BMS, personal fees from MSd, personal fees from novartis, outside the submitted work. JHWd reports personal fees from Actelion, grants and personal fees from Anamar, grants and personal fees from Bayer pharma, grants and personal fees from Boehringer Ingelheim, grants from Celgene, personal fees from Galapagos, grants from GSK, grants and personal fees from Inventiva, personal fees from pfizer, grants and personal fees from UCB, grants from novartis, other from 4d Science, outside the submitted work. JvL reports personal fees from pfizer, grants and personal fees from MSd, personal fees from Eli Lilly, personal fees from BMS, personal fees from roche, outside the submitted work. other coauthors have nothing to disclose.
Publisher Copyright:
©Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc). Methods Between 2000 and 2011, we examined the death certificates of all French patients with SSc to determine causes of death. Then we examined causes of death and developed a score associated with all-cause mortality from the international European Scleroderma Trials and Research (EUSTAR) database. Candidate prognostic factors were tested by Cox proportional hazards regression model by single variable analysis, followed by a multiple variable model stratified by centres. The bootstrapping technique was used for internal validation. Results We identified 2719 French certificates of deaths related to SSc, mainly from cardiac (31%) and respiratory (18%) causes, and an increase in SSc-specific mortality over time. Over a median follow-up of 2.3 years, 1072 (9.6%) of 11 193 patients from the EUSTAR sample died, from cardiac disease in 27% and respiratory causes in 17%. By multiple variable analysis, a risk score was developed, which accurately predicted the 3-year mortality, with an area under the curve of 0.82. The 3-year survival of patients in the upper quartile was 53%, in contrast with 98% in the first quartile. Conclusion Combining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality. We also developed a robust score to risk-stratify these patients and estimate their 3-year survival. With the emergence of new therapies, these important observations should help caregivers plan and refine the monitoring and management to prolong these patients' survival.
AB - Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc). Methods Between 2000 and 2011, we examined the death certificates of all French patients with SSc to determine causes of death. Then we examined causes of death and developed a score associated with all-cause mortality from the international European Scleroderma Trials and Research (EUSTAR) database. Candidate prognostic factors were tested by Cox proportional hazards regression model by single variable analysis, followed by a multiple variable model stratified by centres. The bootstrapping technique was used for internal validation. Results We identified 2719 French certificates of deaths related to SSc, mainly from cardiac (31%) and respiratory (18%) causes, and an increase in SSc-specific mortality over time. Over a median follow-up of 2.3 years, 1072 (9.6%) of 11 193 patients from the EUSTAR sample died, from cardiac disease in 27% and respiratory causes in 17%. By multiple variable analysis, a risk score was developed, which accurately predicted the 3-year mortality, with an area under the curve of 0.82. The 3-year survival of patients in the upper quartile was 53%, in contrast with 98% in the first quartile. Conclusion Combining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality. We also developed a robust score to risk-stratify these patients and estimate their 3-year survival. With the emergence of new therapies, these important observations should help caregivers plan and refine the monitoring and management to prolong these patients' survival.
UR - http://www.scopus.com/inward/record.url?scp=85030983267&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2017-211448
DO - 10.1136/annrheumdis-2017-211448
M3 - Journal articles
C2 - 28835464
AN - SCOPUS:85030983267
SN - 0003-4967
VL - 76
SP - 1897
EP - 1905
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 11
ER -